Guerbet S. A. (PA:GBT) — Market Cap & Net Worth
Market Cap & Net Worth: Guerbet S. A. (GBT)
Guerbet S. A. (PA:GBT) has a market capitalization of $93.47 Million (€79.95 Million) as of September 21, 2026. Listed on the PA stock exchange, this France-based company holds position #19531 globally and #289 in its home market, demonstrating a -1.33% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Guerbet S. A.'s stock price €7.40 by its total outstanding shares 12545738 (12.55 Million). Also see total assets of Guerbet S. A. for a full breakdown of the balance sheet.
Guerbet S. A. Market Cap History: 2015 to 2026
Guerbet S. A.'s market capitalization history from 2015 to 2026. Data shows change from $794.82 Million to $108.54 Million (-15.81% CAGR). Also see Guerbet S. A. (GBT) cash conversion ratio for how efficiently the company converts equity into cash flow.
Index Memberships
Guerbet S. A. is a constituent of 6 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
CAC Mid & Small
CACMS
|
$226.34 Billion | 0.04% | #87 of 119 |
|
CAC Small90
CACS
|
$36.74 Billion | 0.25% | #38 of 64 |
|
CAC All-Tradable
CACT
|
$2.81 Trillion | 0.00% | #147 of 179 |
|
CAC All-Tradable Net Total Return
CACTN
|
$2.81 Trillion | 0.00% | #147 of 179 |
|
CAC All Tradable Gross Total Return
CACTR
|
$2.81 Trillion | 0.00% | #147 of 179 |
|
CAC Health Care
FRHC
|
$239.52 Billion | 0.04% | #23 of 36 |
Weight: Guerbet S. A.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Guerbet S. A. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Guerbet S. A.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of Guerbet S. A. for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.27x
Guerbet S. A.'s market cap is 0.27 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $882.79 Million | $776.47 Million | $28.93 Million | 1.14x | 30.51x |
| 2017 | $993.64 Million | $808.63 Million | $46.22 Million | 1.23x | 21.50x |
| 2018 | $666.72 Million | $794.61 Million | $46.82 Million | 0.84x | 14.24x |
| 2019 | $534.57 Million | $816.91 Million | $37.33 Million | 0.65x | 14.32x |
| 2020 | $433.83 Million | $712.29 Million | $18.24 Million | 0.61x | 23.78x |
| 2021 | $503.83 Million | $735.91 Million | $32.64 Million | 0.68x | 15.44x |
| 2022 | $238.18 Million | $769.50 Million | -$41.12 Million | 0.31x | N/A |
| 2023 | $281.95 Million | $795.65 Million | $23.87 Million | 0.35x | 11.81x |
| 2024 | $393.08 Million | $851.12 Million | $16.08 Million | 0.46x | 24.44x |
| 2025 | $209.74 Million | $786.40 Million | -$108.33 Million | 0.27x | N/A |
Competitor Companies of GBT by Market Capitalization
Companies near Guerbet S. A. in the global market cap rankings as of September 21, 2026. Review Guerbet S. A. (GBT) tangible equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Guerbet S. A. by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #124 globally with a market cap of $178.43 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #228 globally with a market cap of $109.30 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #238 globally with a market cap of $105.53 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #240 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #124 | Abbott Laboratories | NYSE:ABT | $178.43 Billion | $102.61 |
| #228 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $92.13 |
| #238 | Stryker Corporation | NYSE:SYK | $105.53 Billion | $275.12 |
| #240 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Guerbet S. A. Historical Marketcap From 2015 to 2026
Between 2015 and today, Guerbet S. A.'s market cap moved from $794.82 Million to $ 108.54 Million, with a yearly change of -15.81%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €108.54 Million | -48.25% |
| 2025 | €209.74 Million | -46.64% |
| 2024 | €393.08 Million | +39.42% |
| 2023 | €281.95 Million | +18.37% |
| 2022 | €238.18 Million | -52.72% |
| 2021 | €503.83 Million | +16.14% |
| 2020 | €433.83 Million | -18.85% |
| 2019 | €534.57 Million | -19.82% |
| 2018 | €666.72 Million | -32.90% |
| 2017 | €993.64 Million | +12.56% |
| 2016 | €882.79 Million | +11.07% |
| 2015 | €794.82 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 21st, 2026 the market cap of Guerbet S. A. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $93.47 Million USD |
| MoneyControl | $93.47 Million USD |
| MarketWatch | $93.47 Million USD |
| marketcap.company | $93.47 Million USD |
| Reuters | $93.47 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Guerbet S. A.
Guerbet SA provides a range of contrast media, medical devices, and digital and AI solutions for diagnostic and interventional imaging worldwide. It offers DOTAREM, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced MRI examinations; Elucirem, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced resonance imaging; UNIK, a diagnostic imaging interconne… Read more